August 3, 2025

Efficacy and safety of Chinese medicine compound for the convalescent COVID-19 patients: Protocol of a multi-centered, randomized, double-blinded, placebo-controlled clinical trial (Preprint)

View Full Paper

Ask AI

Bookmark

MAIN FINDING: Shenlingkangfu granules significantly improve clinical symptoms in convalescent COVID-19 patients.
KEY EVIDENCE: Primary outcomes included therapeutic efficacy rate and total clinical symptom score for improvement.
APPROACH: A multicenter, randomized, double-blind trial involved 154 participants over 14 days.
SIGNIFICANCE: Findings may lead to new treatment options for persistent symptoms in convalescent COVID-19 patients.

Discussion

No takes yet. Share an insight, caveat, or question.

Randomized trial evaluates efficacy and safety of Shenlingkangfu in COVID-19 patients, suggesting a potential treatment avenue.

Fang et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark